Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CTX-4430
CNS Pharmaceuticals
Acne Vulgaris
1 trial -
CYCLOPHOSPHAMIDE, PREDNISOLONE , Golcadomide, VINCRISTINE SULFATE, PEGFILGRASTIM, RITUXIMAB, Golcadomide, DOXORUBICIN, Golcadomide, VINCRISTINE SULFATE, RITUXIMAB, Golcadomide, PREDNISONE, BENDAMUSTINE HYDROCHLORIDE
Celgene Europe Limited
Newly Diagnosed Advanced Stage Follicular Lymphoma
1 trial -
Celgosivir
60 DEGREES PHARMACEUTICALS, INC.
Dengue Fever
1 trial -
DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Empliciti 400 mg powder for concentrate for solution for infusion., Dexamethason CF 20 mg/ml, injectievloeistof, Dexamethasone 2mg Tablets, VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, Dexamethason 4 mg JENAPHARM®, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, CC-92480, CC-92480
Celgene Europe Limited
Relapsed or refractory multiple myeloma (RRMM) and newly diagnosed MM (NDMM)
1 trial -
DEXAMETHASONE , PEGFILGRASTIM , Mosunetuzumab, DIPHENHYDRAMINE , RASBURICASE , Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, PREDNISONE , FLUDEOXYGLUCOSE (18F) , METHYLPREDNISOLONE, MabThera 500 mg concentrate for solution for infusion, PARACETAMOL, ALLOPURINOL
Hoffmann-La Roche
B-cell non-Hodgkin lymphoma (NHL)
1 trial -
DEXAMETHASONE, ELRANATAMAB, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480, CC-92480
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
Delgocitinib cream, Cream Vehicle
LEO Pharma A/S
Mild to severe palmoplantar pustulosis
1 trial -
Dexamethason 4 mg JENAPHARM®, CC-92480, CC-92480, CC-92480, CC-92480, Dexamethason-ratiopharm® 4 mg Tabletten, TAZEMETOSTAT, CC-92480, Mekinist 2 mg film-coated tablets, Dexamethason 4 mg GALEN®, Mekinist 0.5 mg film-coated tablets, BET-Inhibitor, CC-92480
Celgene Europe Limited
Relapsed or Refractory Multiple Myeloma (RRMM)
1 trial -
Enasidenib Mesilate, Enasidenib Mesilate, Ivosidenib, Vidaza 25 mg/ml powder for suspension for injection
Celgene Europe Limited
Acute Myeloid Leukemia (AML)
1 trial -
FCD105
VYNE Therapeutics
Acne Vulgaris
1 trial -
Filgotinib
Lakefront Biotherapeutics NV
Fistulizing Crohn's Disease
1 trial -
Filgotinib
Lakefront Biotherapeutics NV
Inflammatory Bowel Disease
1 trial -
Filgotinib
Lakefront Biotherapeutics NV
Small Bowel Crohn's Disease
1 trial -
Filgotinib
Lakefront Biotherapeutics NV
Noninfectious Uveitis
1 trial -
Fremanezumab
Teva Pharma GmbH
Fibromyalgia
1 trial -
HB0043
The First People's Hospital of Lianyungang
Acne Vulgaris
1 trial -
INTERFERON GAMMA , TOCILIZUMAB , DALTEPARIN , HEPARIN , BARICITINIB, FLUDROCORTISONE , HYDROCORTISONE, OCTAPLASLG, solution pour perfusion, BARICITINIB, ANAKINRA , FILGRASTIM
Pari Pharma GmbH
Sepsis
1 trial -
IOBENGUANE (123I) , [18F]meta-fluorobenzylguanidine
AXIM BIOTECHNOLOGIES, INC.
(suspision on) Neuroblastoma
1 trial -
Iberdomide, Iberdomide, Iberdomide, Iberdomide, Dexamethasone Tablets BP 2.0mg, Iberdomide, Iberdomide, Iberdomide, Dexamethasone 2mg Tablets , Iberdomide, Iberdomide, DARZALEX 1800 mg solution for injection, Iberdomide, Iberdomide, Iberdomide, Dexamethason-ratiopharm® 4 mg Tabletten
Celgene Europe Limited
Multiple Myeloma
1 trial -
Imsidolimab
Vanda Pharmaceuticals Netherlands B.V.
Acne Vulgaris
1 trial -
JCAR017
Celgene Europe Limited
Lymphoma, Non-Hodgkin
1 trial -
Jueyin granules
The First People's Hospital of Lianyungang
Psoriasis Vulgaris
1 trial -
LEO 90105
LEO Pharma A/S
Psoriasis Vulgaris
1 trial -
LGD-6972-5 mg
LIGAND PHARMACEUTICALS INC
Type 2 Diabetes Mellitus
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources